PrEP

The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.

The HIV In-hospital Mortality Prediction (HIV-IMP) risk score showed good discrimination and calibration and may be useful in guiding clinical decision-making.

A recent study measured premature deaths among people with HIV by sex, race, and HIV risk factor.

This investigational therapy could be the first implantable form of PrEP.

People who inject drugs are at high-risk for HIV infection, but very few are interested in PrEP prescriptions.

If the company gets approval it would be the first dispersible single tablet regimen containing dolutegravir.

As more agents expand the capability and variety of PrEP options, investigators consider what questions remain about the drug class.

A conversation in consideration of the high-risk psychosocial comorbidities the aging HIV population may face through COVID-19.

An expert reviews cabotegravir, islatravir, lenacapavir, and what other promising agents that could redefine long-term HIV prevention.

Mortality rates of children with HIV may be underreported due to lack of patient follow-up and the usage of routine program data.

Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.

Research suggests studies should adjust their cohort comparison group to account for demographics most represented by people living with HIV.

The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.

England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.

Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.

The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.

To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.

Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

Higher HIV viral loads and additional heart disease factors increase the risk as well.

A small subset of people living with HIV (PLWH) can naturally suppress the virus without medication.

Changes in perceptions about the severity of HIV with advances in treatment and efforts to normalize living with the disease may create challenges for HIV prevention, a new study from the Netherlands suggests.

Islatravir exerts multiple mechanisms against HIV, demonstrates treatment effectiveness with doravirine, and is a potential weekly or monthly oral PrEP.

Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.

Despite heightened cardiovascular disease (CVD) risk, too few get drugs at appropriate dose, researchers say.